Evidence map›Paper›PMID 32203141›Full record

Trial reportLeukemia2021

Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.

O Al-Sawaf, S Robrecht, J Bahlo, A M Fink, P Cramer, J V Tresckow, E Lange, M Kiehl, M Dreyling, M Ritgen and 9 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

O Al-SawafDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany. othman.al-sawaf@uk-koeln.de.ORCID http://orcid.org/0000-0001-9895-0570
S RobrechtDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
J BahloDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
A M FinkDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
P CramerDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
J V TresckowDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
E LangeDepartment of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany.
M KiehlDepartment of Internal Medicine, Frankfurt (Oder) General Hospital, Frankfurt/Oder, Germany.
M DreylingDepartment of Medicine III, University Hospital Ludwig Maximilians University, Munich, Germany.
M RitgenSecond Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.
J DürigDepartment of Hematology, University Hospital Essen, Essen, Germany.
E TauschDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
C SchneiderDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
S StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
C M WendtnerDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, German CLL Study Group, Munich Clinic Schwabing, Munich, Germany.
K FischerDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
GoedeDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
M HallekDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany.
B EichhorstDepartment I of Internal Medicine and Center of Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Duesseldorf, Cologne, Germany. barbara.eichhorst@uk-koeln.de.
University of Cologne · DEUniversität Ulm · DEEssen University Hospital · DEEvangelisches Krankenhaus Hamm · DEGoethe University Frankfurt · DELudwig-Maximilians-Universität München · DEUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1-69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09-3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.

Indexed as

Cell Transformation, NeoplasticAdultAgedAged, 80 and overBiopsyDisease ProgressionFemaleGenetic VariationGermanyHumansLeukemia, Lymphocytic, Chronic, B-CellLymphomaMaleMiddle AgedNeoplasm GradingNeoplasm Staging

Identifiers

PMID32203141
OpenAlexW3011082834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.